Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
03/2003
03/27/2003CA2460456A1 Chromogenic in situ hybridization methods, kits, and compositions
03/27/2003CA2460334A1 Microfabricated nanopore device for sustained release of therapeutic agent
03/27/2003CA2460321A1 Chemokines as adjuvants of immune response
03/27/2003CA2460319A1 Lpa receptor agonists and antagonists and methods of use
03/27/2003CA2460244A1 Simplified sarcodictyn derivatives as anti-tumor agents
03/27/2003CA2460151A1 Cytokine receptor
03/27/2003CA2460125A1 Novel compounds and compositions as cathepsin inhibitors
03/27/2003CA2460120A1 Compositions and methods for the diagnosis and treatment of tumor
03/27/2003CA2459140A1 Protein modification and maintenance molecules
03/27/2003CA2459022A1 Neurotransmission-associated proteins
03/27/2003CA2456193A1 Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies
03/27/2003CA2454023A1 Dna-pk inhibitors in the treatment of retroviral mediated diseases
03/27/2003CA2429005A1 Substituted benzoic acid derivatives having nf-kb inhibiting action
03/27/2003CA2423885A1 Thiazole and oxazole derivatives
03/26/2003EP1295939A1 Insulin-like growth factor binding protein
03/26/2003EP1295897A1 DNA encoding the chimpanzee prostaglandin E2 receptor EP4 subtype
03/26/2003EP1295878A1 Novel pyrazinone derivatives
03/26/2003EP1295607A1 Antitumor effect potentiators
03/26/2003EP1295597A1 Antitumour compositions containing taxan derivatives
03/26/2003EP1294928A1 Screening method for modulators of suv39h2-methyltransferase
03/26/2003EP1294927A1 Screening-method for modulators of methyltransferase-dependent chromosome stability
03/26/2003EP1294924A2 Method for identifying medically valuable active substances
03/26/2003EP1294922A2 Method for treating cancer, visualizing cell structures, and isolating organelles using organelle crystallizing agents
03/26/2003EP1294918A2 Replication deficient adenoviral tnf vector
03/26/2003EP1294905A1 Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest
03/26/2003EP1294904A1 Heterodimeric fusion proteins
03/26/2003EP1294901A2 Novel proteases
03/26/2003EP1294885A2 B7-like molecules and uses thereof
03/26/2003EP1294884A2 Secretion and trafficking molecules
03/26/2003EP1294883A2 Human extracellular matrix (ecm)-related tumor marker
03/26/2003EP1294876A2 Eg-vegf nucleic acids and polypeptides and methods of use
03/26/2003EP1294874A2 Cd154 variants and uses thereof
03/26/2003EP1294873A1 Tumour suppressor and uses thereof
03/26/2003EP1294871A1 Secreted epithelial colon stromal-1 polypeptides, nucleic acids encoding the same and uses thereof
03/26/2003EP1294769A1 Antibodies that immunospecifically bind to blys
03/26/2003EP1294765A2 Il-17 molecules and uses thereof
03/26/2003EP1294756A2 Biosynthetic oncolytic molecules and uses therefor
03/26/2003EP1294754A1 Interferon-alpha induced gene
03/26/2003EP1294752A2 Angiogenesis-modulating compositions and uses
03/26/2003EP1294750A2 Acid-modified arabinogalactan protein composition
03/26/2003EP1294747A2 Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them
03/26/2003EP1294742A2 Urokinase inhibitors
03/26/2003EP1294737A1 Antisense modulation of c/ebp beta expression
03/26/2003EP1294732A1 Ruthenium (ii) compounds for use in the therapy of cancer
03/26/2003EP1294728A1 HMG-CoA REDUCTASE INHIBITORS AND METHOD
03/26/2003EP1294726A2 Improvements in and relating to chromophores
03/26/2003EP1294725A2 Multicyclic compounds and the use thereof as inhibitors of parp, vegfr2 and mlk3 enzymes
03/26/2003EP1294724A1 Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents
03/26/2003EP1294721A1 Cyclic gmp-specific phosphodiesterase inhibitors
03/26/2003EP1294718A2 6,5-fused bicyclic heterocycles
03/26/2003EP1294715A1 Quinazoline ditosylate salt compounds
03/26/2003EP1294714A2 Thrombin receptor antagonists
03/26/2003EP1294713A2 Compounds possessing antibacterial, antifungal or antitumor activity
03/26/2003EP1294711A2 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as as modulators of protein kinases
03/26/2003EP1294709A2 Quinoline derivatives and their use as aurora 2 kinase inhibitors
03/26/2003EP1294707A2 Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
03/26/2003EP1294704A1 Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
03/26/2003EP1294699A2 Modulators of tnf- alpha signalling
03/26/2003EP1294696A2 Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases
03/26/2003EP1294691A1 Serine protease inhibitors
03/26/2003EP1294690A2 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
03/26/2003EP1294688A2 Indolinone derivatives as protein kinase/phosphatase inhibitors
03/26/2003EP1294687A2 1,2,4-trisubstituted benzenes as inhibitors of 15-lipoxygenase
03/26/2003EP1294686A2 Indole derivatives and their use as 15-lipoxygenase inhibitors
03/26/2003EP1294681A2 Fmoc-l-leucine and derivatives thereof as ppar- gamma agonists
03/26/2003EP1294679A1 Beta-amino acid nitrile derivatives
03/26/2003EP1294646A2 Devices and method for production of traceable immunizing drinking water, other liquids and gas
03/26/2003EP1294409A2 Membrane-permeant peptide complexes for medical imaging
03/26/2003EP1294406A2 Modulation of chromosome function by chromatin remodeling agents
03/26/2003EP1294405A2 Prodrug compounds cleavable by thimet oligopeptidase
03/26/2003EP1294404A2 Prodrug compounds with an oligopeptide having an isoleucine residue
03/26/2003EP1294403A2 Tripeptide prodrug compounds
03/26/2003EP1294401A2 Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
03/26/2003EP1294398A2 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
03/26/2003EP1294397A2 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
03/26/2003EP1294391A2 Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion
03/26/2003EP1294389A1 THERAPEUTICAL USE OF i SOPHORA FLAVESCENS /i OR i SOPHORA SUBPROSTRATA /i EXTRACTS
03/26/2003EP1294388A1 EXTRACTS FROM i SOPHORA /i SPECIES, METHOD FOR PRODUCING THE SAME AND THEIR USE
03/26/2003EP1294384A2 Use of lanthanum compounds for the treatment of bone diseases
03/26/2003EP1294370A2 Triterpenoid derivatives
03/26/2003EP1294365A2 Cytotoxic agents comprising single-stranded and/or looped dna
03/26/2003EP1212315B1 Novel chalcones
03/26/2003EP1212311B1 Chalcone coumarins
03/26/2003EP1150701A4 Homing pro-apoptotic conjugates and methods of using same
03/26/2003EP1146873A4 Anti-androgens and methods for treating disease
03/26/2003EP1105384B1 Diarylbenzopyran derivatives as cyclooxygenase-2 inhibitors
03/26/2003EP1098631B1 Pharmaceutical composition in particular for preventing and treating mucositis induced by radiotherapy or chemotherapy
03/26/2003EP1091948B1 Tubulin binding compounds (cobra)
03/26/2003EP1007029A4 Methods and compositions for treatment of ovarian cancer
03/26/2003EP0998454B1 Metalloproteinase inhibitors
03/26/2003EP0977735B1 Vitronectin receptor antagonists
03/26/2003EP0969822B1 Determination of the propensity of an organ or tissue for cancer by determining of its imprinting pattern
03/26/2003EP0939809B1 Tie-2 receptor ligand (tie ligand-4) and its use
03/26/2003EP0763026B1 Gastrin and cck antagonists
03/26/2003CN1406280A Progenitor cell preservation factors and related methods and products
03/26/2003CN1406238A A novel crystalline form of N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo [2,3-d] pyrimidin-5-yl) ethyl] benzoyl]-L-glutamic acid and process therefor
03/26/2003CN1406231A Pyrimidine compounds
03/26/2003CN1406230A 2,4-di (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents
03/26/2003CN1406229A Pyrimidine compounds
03/26/2003CN1406227A Aryl fused azapolycy clic compounds
1 ... 1586 1587 1588 1589 1590 1591 1592 1593 1594 1595 1596 1597 1598 1599 1600 1601 1602 1603 1604 1605 1606 ... 2211